New Myopia Control Lenses Show Promise in Early Trial
Children using the new lenses saw six-month results comparable to a year of original lens wear.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Do you believe parents should pursue clinical management to slow their child's myopia progression?
Interim results from a clinical trial show that children wearing Essilor Stellest 2.0 lenses for six months experienced myopia progression reduction comparable to a full year of wear with original lenses. These glasses are designed to slow eye growth in young children, though they have not yet been cleared by the FDA.
Why it matters
Managing myopia progression in childhood is critical for long-term eye health as high levels of nearsightedness can increase the risk of eye diseases later in life. New lens technologies that effectively slow axial eye growth offer parents and clinicians additional options for long-term vision management.
In an interim clinical trial, children wearing Essilor Stellest 2.0 lenses for six months saw 0.51 D lower myopia progression and 0.21 mm less axial elongation than those in single-vision lenses. While preliminary, these results are comparable to one-year outcomes from original lenses.
The players
EssilorLuxottica
A multinational corporation that manufactures vision care products, including ophthalmic lenses and frames.
European Society of Cataract and Refractive Surgeons
A professional society for ophthalmologists that hosts international symposia on vision research and surgical practice.
The details
The lenses utilize HALT Max technology, which is engineered to slow the axial elongation—the lengthening of the eyeball—that drives nearsightedness. To achieve these results, study participants adhered to a strict usage protocol, wearing the corrective lenses for at least 10 hours daily for a minimum of 6 days per week. The technology aims to provide consistent vision correction while managing the eye's physical growth during critical development years.
Timeline
• 6 months: Duration of the clinical trial for Essilor Stellest 2.0 lenses.
• 1 year: Comparison timeframe for original lens myopia progression reduction.
• 2 years: Duration of the study measuring original Stellest lens treatment effects.
Health Landscape
The introduction of new corrective lenses reflects a broader move toward myopia management using specialized optical designs to control ocular growth. This development extends the established clinical performance of Essilor Stellest lenses by demonstrating faster results with the updated 2.0 technology.
Parents considering options to slow nearsightedness in children should discuss the latest clinical findings with an eye care professional, as these specific 2.0 lenses are not yet available for general use. It is important to confirm that any myopia control strategy is appropriate for a child's unique vision needs and lifestyle.
The takeaway
New lens technology appears to offer a faster clinical reduction in childhood myopia progression compared to previous versions. Parents should consult their child's optometrist or ophthalmologist to discuss evidence-based myopia management strategies appropriate for their child's specific developmental stage.
Further reading
Learn more about the latest innovations in Asthma management and vision health.
Live Poll
Do you believe parents should pursue clinical management to slow their child's myopia progression?
